Figure 5.

Vascularized tumoroids from patient‐derived breast TCs respond differently to interventions normalizing vascular and stromal HA. a) Projected confocal microscopy images of patient‐derived tumoroids show distinct levels of vascularization and TC invasion. b) Permeability of patient‐derived tumoroid MVNs; n = 3–4. c) Cell death in the patient‐derived tumoroids as a function of combined treatment with trastuzumab + cetuximab (“mAB”) with different strategies targeting vascular and stromal HA, as measured by proxy of fluorescent SYTOX intensity; n = 3–4. Significance assessed by one‐way ANOVA after confirming a normal distribution of the data; p < 0.05 *, p < 0.01 **, p < 0.001 ***.